Haisco Pharmaceutical Group Co. Ltd. has described compounds acting as integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Researchers at Inventisbio Co. Ltd. and Inventisbio LLC have described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
Recludix Pharma Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a signal transducer and activator of transcription 3 (STAT3) targeting moiety via a linker acting as STAT3 degradation inducers reported to be useful for the treatment of cancer and inflammatory disorders.
Scientists at Beigene Ltd. and Beigene Switzerland GmbH have identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA related overgrowth spectrum (PROS).
Several recent Celgene Corp. patents detail the development of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety via a linker.
Work at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. has led to the discovery of new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast cancer and castration-resistant prostate cancer.
RSS